How frequently should echocardiographic global longitudinal strain be monitored during chemotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Echocardiographic GLS Monitoring Frequency During Chemotherapy

Monitor echocardiographic global longitudinal strain (GLS) every 3 months during chemotherapy, particularly during the first year of treatment for patients receiving cardiotoxic agents like anthracyclines and HER2-targeted therapies. 1, 2

Standard Monitoring Protocol

The evidence-based monitoring schedule is:

  • Baseline: Before starting chemotherapy
  • During treatment: Every 3 months for the first year 2
  • Post-treatment: At completion, then at 6 months and 1 year 1

For patients on HER2-targeted therapies (like trastuzumab), cardiovascular assessment including GLS should occur every 3 months during the first year of treatment 2. This is a quality indicator established by the European Society of Cardiology.

Intensified Monitoring Scenarios

If cardioprotective medications are initiated (beta-blockers or ACE inhibitors/ARBs), increase monitoring frequency to monthly intervals 1. This applies when:

  • EF drops below 50%
  • EF decreases by >10%
  • GLS shows abnormal changes (>15% relative reduction) 1
  • Troponin becomes abnormal

Clinical Significance of GLS Changes

A >15% relative reduction in GLS is the critical threshold that predicts subsequent cardiotoxicity and warrants intervention 1, 3. For example, if baseline GLS is -20%, a reduction to -17% or worse (15% relative change) is significant.

Research demonstrates that GLS detects myocardial dysfunction as early as 1-3 months after treatment initiation, well before LVEF changes become apparent 4. In the intervention study by 3, GLS-guided management reduced trastuzumab discontinuation from 24% to 2.4% (p=0.009), validating the clinical utility of this monitoring approach.

Important Technical Considerations

  • Temporal variability of GLS in stable patients is approximately 1.3%, with a maximum detectable difference of 3.2-3.6% 5
  • Use 3 apical views (not single-view) for GLS measurement, as single-view assessments led to 15-22% disagreement in cardiotoxicity diagnosis 6
  • GLS has superior reproducibility (coefficient of variance 2.9-3.7%) compared to single-chamber measurements 6

Symptom-Driven Monitoring

Beyond scheduled intervals, obtain echocardiography with GLS assessment immediately if cardiac symptoms develop at any time during or after treatment 1. Do not wait for the next scheduled assessment.

Long-Term Surveillance

For patients who complete therapy without developing cardiotoxicity, obtain post-therapy assessment and repeat echocardiography at 6 months or 1 year 1. If abnormalities persist, follow ACC/AHA heart failure guidelines for ongoing management.

Related Questions

In a patient with a history of cancer treated with multiple courses of radiation and chemotherapy who now has a normal left ventricular ejection fraction (~59%) but moderately reduced global longitudinal strain (~‑12%) and otherwise normal cardiac function, what is the next best step in cardiac management?
What does it mean when a standard echocardiogram shows normal left ventricular wall motion and normal left ventricular systolic function but the global longitudinal strain is –11%?
How frequently should echocardiograms be performed in a patient receiving pemetrexed, carboplatin, and osimertinib (Tagrisso)?
What are the latest 2026 ESC (European Society of Cardiology) guideline recommendations?
Based on the echocardiogram showing normal left ventricular size with moderate wall thickening and concentric hypertrophy, reduced global longitudinal strain, mildly dilated left and right atria, mildly thickened valve leaflets with trace regurgitation, and a mildly enlarged ascending aorta, what additional diagnostic and management recommendations should be made?
What alternative antibiotics can be used to treat uncomplicated typhoid fever in children who cannot receive azithromycin?
What are the indications for using urinary alkalinizers (alkalinizing agents) in children?
Is betahistine contraindicated in patients with a seizure disorder?
What is retroperitoneal lymph‑node dissection (RPLND) in the management of non‑seminomatous germ‑cell tumor (NSGCT)?
Why do fistulous tracts develop in actinomycosis and what is their clinical appearance?
In a married woman with a negative pregnancy test undergoing cervical or circular cervical encirclage, is administration of NDD (neonatal drug delivery) indicated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.